Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNASDAQ:BFRGNASDAQ:EDSANASDAQ:LPCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.83-9.1%$0.93$0.46▼$7.49$4.31M-0.24615,005 shs104,377 shsBFRGBullfrog AI$1.66$2.05$1.23▼$4.84$15.63M0.77387,196 shs222,420 shsEDSAEdesa Biotech$2.26-3.4%$2.37$1.55▼$5.59$15.80M0.6491,535 shs4,163 shsLPCNLipocine$3.00-0.3%$3.27$2.75▼$11.79$16.05M1.5132,886 shs4,104 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group0.00%+5.24%-14.30%-27.71%-88.53%BFRGBullfrog AI0.00%-20.95%-7.78%-21.70%-43.15%EDSAEdesa Biotech0.00%+0.44%-8.13%+32.16%-47.93%LPCNLipocine0.00%-2.28%-18.48%-31.35%-43.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.5577 of 5 stars0.05.00.00.02.81.70.6BFRGBullfrog AI0.608 of 5 stars0.03.00.00.01.52.50.0EDSAEdesa Biotech3.1964 of 5 stars3.55.00.00.03.31.70.6LPCNLipocine2.6388 of 5 stars3.55.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ABFRGBullfrog AI 0.00N/AN/AN/AEDSAEdesa Biotech 3.00Buy$21.00829.20% UpsideLPCNLipocine 3.00Buy$10.00233.33% UpsideCurrent Analyst Ratings BreakdownLatest APM, BFRG, LPCN, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K10.02N/AN/A$2.97 per share0.28BFRGBullfrog AI$60K260.48N/AN/A$0.43 per share3.86EDSAEdesa BiotechN/AN/AN/AN/A$0.18 per shareN/ALPCNLipocine$11.20M1.43N/AN/A$3.83 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$2.83MN/A0.00∞N/AN/AN/AN/A4/28/2025 (Estimated)BFRGBullfrog AI-$5.36M-$0.86N/A∞N/AN/A-141.39%-124.63%5/9/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.87N/AN/AN/AN/A-233.69%-124.14%5/9/2025 (Estimated)LPCNLipocine-$16.35M-$0.01N/A∞N/AN/A-19.17%-17.60%5/7/2025 (Estimated)Latest APM, BFRG, LPCN, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025N/AEDSAEdesa Biotech-$0.30N/AN/AN/AN/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/A2/14/2025Q1 2025EDSAEdesa Biotech-$0.31-$0.48-$0.17-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum Group0.241.16N/ABFRGBullfrog AIN/A5.905.90EDSAEdesa BiotechN/A1.090.91LPCNLipocineN/A12.9712.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%BFRGBullfrog AI0.96%EDSAEdesa Biotech5.50%LPCNLipocine9.11%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%BFRGBullfrog AI33.90%EDSAEdesa Biotech22.60%LPCNLipocine6.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.18 million1.87 millionNot OptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableEDSAEdesa Biotech206.99 million2.60 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataAPM, BFRG, LPCN, and EDSA HeadlinesRecent News About These CompaniesLipocine (NASDAQ:LPCN) Share Price Crosses Below 200-Day Moving Average - What's Next?April 15, 2025 | americanbankingnews.comL’action LPCN atteint son plus bas niveau sur 52 semaines à 2,91$April 7, 2025 | fr.investing.comLipocine Inc. Reports 2024 Financial TurnaroundApril 4, 2025 | tipranks.comLipocine’s Phase III trial of LPCN 1154 to begin for postpartum depressionMarch 27, 2025 | finance.yahoo.comLipocine initiates Phase 3 trial for LPCN 1154March 27, 2025 | markets.businessinsider.comLipocine annonce le début de l'étude de phase 3 en ambulatoire sur la dépression post-partum avec le LPCN 1154March 26, 2025 | zonebourse.comLipocine Inc. annonce le début de l'essai de phase 3 sur la dépression post-partum en consultation externe du LPCN 1154March 26, 2025 | zonebourse.comLipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154March 26, 2025 | prnewswire.comLIPOCINE Earnings Results: $LPCN Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comLipocine Says FDA Recommends Removing Cardiovascular Risk Warning From Testosterone Product LabelsMarch 14, 2025 | nasdaq.comLipocine announces US FDA labelling changes for testosterone productsMarch 13, 2025 | pharmabiz.comLipocine Announces Financial Results for the Full Year Ended December 31, 2024March 13, 2025 | prnewswire.comLipocine Inc.: Lipocine Announces FDA Labeling Changes for Testosterone ProductsMarch 12, 2025 | finanznachrichten.deLipocine Inc. annonce des changements d'étiquetage de la FDA pour les produits à base de testostéroneMarch 12, 2025 | zonebourse.comLipocine Announces FDA Labeling Changes for Testosterone ProductsMarch 12, 2025 | prnewswire.comL’action LPCN atteint son plus bas niveau sur 52 semaines à 2,92$March 5, 2025 | fr.investing.comLPCN stock touches 52-week low at $3.15 amid market challengesFebruary 26, 2025 | investing.comL'action LPCN atteint son plus bas niveau sur 52 semaines à 3,15$February 24, 2025 | fr.investing.comLipocine planifie une étude de phase 3 pour son médicament contre la dépression post-partumFebruary 6, 2025 | fr.investing.comLipocine Inc. reçoit des directives réglementaires actualisées sur le LPCN 1154February 6, 2025 | zonebourse.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPM, BFRG, LPCN, and EDSA Company DescriptionsAptorum Group NASDAQ:APM$0.83 -0.08 (-9.14%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$0.84 +0.01 (+1.41%) As of 04/17/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Bullfrog AI NASDAQ:BFRG$1.66 0.00 (0.00%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 04/17/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Edesa Biotech NASDAQ:EDSA$2.26 -0.08 (-3.42%) Closing price 04/17/2025 03:53 PM EasternExtended Trading$2.26 +0.01 (+0.22%) As of 04/17/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Lipocine NASDAQ:LPCN$3.00 -0.01 (-0.33%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.21 +0.21 (+6.97%) As of 04/17/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/14 - 04/18 Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
